Eli Lilly, just weeks after snaring approval for dual GIP/GLP-1 med Mounjaro in Type 2 diabetes, is trumpeting its case for the nascent blockbuster in weight loss. The data likely portend a clash with ...
The FierceBiotech team tackled coverage of drug-development news and events at the American Diabetes Association annual meeting in Chicago, where I met with leaders in the field and, as a matter of ...
Eli Lilly and Company has announced that the data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented ...
Chalk another one up for Eli Lilly’s next-generation diabetes drug. All three doses of tirzepatide beat placebo at lowering blood sugar and body weight in adults with early-stage Type 2 diabetes, more ...
Eli Lilly has several products with growth potential and especially recently introduced Mounjaro could reach blockbuster status quickly. The company is also a recession-resilient business. Eli Lilly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback